Meropenem
- Generic Name
- Meropenem
- Brand Names
- Vabomere
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O5S
- CAS Number
- 96036-03-2
- Unique Ingredient Identifier
- YOP6PX0BAO
- Background
Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.
...
- Indication
For use as single agent therapy for the treatment of the following infections when caused by susceptible isolates of the designated microorganisms: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, vi...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Meningitis, Bacterial, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin infection bacterial
- Associated Therapies
- -
Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2012-06-29
- Lead Sponsor
- Kompetenznetz Sepsis
- Target Recruit Count
- 600
- Registration Number
- NCT00534287
- Locations
- 🇩🇪
Klinikum Oldenburg - Dep. of Anesthesiology, Intensive Care Medicine, Emergency Medicine, Pain Therapy, Oldenburg, Germany
🇩🇪University Hospital Ulm - Dep. of Internal Medicine II, Ulm, Germany
🇩🇪University Hospital Münster - Dep. of Anesthesiology and Intensive Care Medicine, Münster, Germany
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2009-05-12
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 392
- Registration Number
- NCT00462878
- Locations
- 🇪🇸
Hospital Universitario de Canarias, Tenerife, Canarias, Spain
🇪🇸Hospital Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Verge de la Cinta, Tortosa, Tarragona, Spain
Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion
- Conditions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2008-06-09
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 40
- Registration Number
- NCT00435305
- Locations
- 🇩🇪
Universitäsklinikum Tübingen, Klinik für Anästhesiologie und Intensivmedizin, Tübingen, Germany
Pharmacoeconomic Analysis of First Line Meropenem Versus Standard Antibiotic Treatment in Seriously Infected Secondary Nosocomial Sepsis Syndrome Patients.
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT00318552
- Locations
- 🇭🇺
Research Site, Veszprem, Hungary
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00318994
- Locations
- 🇨🇴
Research Site, Bogota, Colombia
Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU
- Conditions
- Interventions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2013-06-07
- Target Recruit Count
- 460
- Registration Number
- NCT00307099
- Locations
- 🇺🇸
Washington University in St. Louis, St. Louis, Missouri, United States
🇺🇸Akron General Medical Center- Medicine, Akron, Ohio, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
A Study to Determine if Antibiotics Prevent Infection in the Pancreas of Patients Where Part of the Pancreas Has Died
- Conditions
- First Posted Date
- 2003-05-28
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT00061438
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.